35 results about "Neurotransmission" patented technology

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

A composition of a compound represented by FIGS. 1A-1E for use in treating a medical disorder. A method of changing neurotransmission, by administering a pharmaceutically effective amount of composition to a mammal of a compound represented by FIGS. 1A-1E and inducing psychoactive effects in the mammal. A method of treating a patient having adverse reactions to psychedelics or entactogens, by administering a pharmaceutically effective amount of composition to the patient of a compound represented by FIGS. 1A-1E and avoiding adverse effects present with psychedelics or entactogens.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The present invention provides a method and pharmaceutical composition for treating overactive bladder (OAB) and / or bladder pain syndrome (BPS) comprising a viral expression vector carrying a transcription cassette containing a transgene that inhibits / silences neurotransmission or synaptic transmission of an afferent neuron.

The present invention is directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives, advantageously for use in the prevention or treatment of neurological, psychiatric and sleep disorders and diseases in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds for use in the prevention and / or treatment of neurological disorders and diseases. The present invention is also directed to dihydroquinazoline, -benzothiazine and -benzoxazine derivatives and the use of these compounds as medicaments.

An implantable stimulation system is provided having a stimulation unit coupled to a programmable controller, a stimulation circuit, and an electrode array disposed on a pair of flexible blades for selectively stimulating at least one pelvic nerve, such as a cavernous nerve. The implantable stimulation system may be programmed to run a first sequence of stimulation pulses, the first stimulation pulse sequence corresponds to a first pattern for inducing a rapid erection reaction to achieve sexual behavior and potential ejaculation, a second pattern for inducing a rapid erection reaction sufficient to facilitate a medical procedure, such as applying a catheter, a third neurological rehabilitation stimulation pattern for restoring neurotransmission to treat urinary incontinence and / or intestinal dysfunction, and / or a fourth penis rehabilitation pattern for reducing penis fibrosis. A method of operating the system is also provided.

In nerve diseases, cell dysfunction due to amyloid aggregate accumulation in nerve cells has attracted attention, but dysfunction of nerve axons responsible for neurotransmission is also considered to be one of the causes. However, no therapeutic agent that focuses on the repair and maintenance of nerve axons has been found. An object of the present invention is to provide a therapeutic agent that activates oligodendrocytes having a function of preserving nerve axons.SOLUTION: Transcriptome analysis with a psychotropic drug is carried out using an oligodendrocyte marker as an indicator, and it is found that the combined use of DPZ and NFN characteristically increases the expression of a transcriptional factor OLIG1 inducing the differentiation-maturation of the oligodendrocyte. Moreover, the drug concentration at this time was much lower than the expected clinical dose. The combined use of NFN and DPZ was observed to improve spatial memory in the mouse Y-maze test. The combination of NFN and DPZ can provide a novel treatment for cognitive and memory functions associated with neurological disorders.SELECTED DRAWING: None

This invention belongs to the field of biomedicine and discloses estradiol derivatives or pharmaceutically acceptable salts thereof with the structure shown in Formula I: R is selected from R1, which is selected from F, Cl, Br, and I; L is selected from straight-chain or branched alkyl groups with 2 to 10 carbon atoms. This invention also discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating depression and anxiety. Furthermore, this invention discloses the use of the estradiol derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs targeting ERβ / SERT for treating depression and anxiety. The estradiol derivatives of this invention can simultaneously and effectively inhibit SERT and activate ERβ, thereby synergistically enhancing serotonergic neurotransmission and regulating neuroplasticity, and enhancing antidepressant efficacy through multi-target synergistic effects.

The present invention provides N-substituted phenylalkylamines, methods of making the same, and methods of using such compounds, e.g., as receptor probes, as neurotransmission modulators, and as therapeutic agents, e.g., as central nervous system drugs. Also provided are pharmaceutical compositions and methods for their use in the treatment of certain diseases, such as serotonin neurotransmitter diseases, mental health disorders, and ion channel mediated diseases, such as seizure disorders.

The present disclosure relates to the use of compounds of formula (I), compounds of formula (II), and related analogs for enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex), and to methods of enhancing neurogenesis, enhancing neurite outgrowth, enhancing nerve growth, nerve connectivity, synaptic density, dendritic spine density, dendritic spine size, and excitatory neurotransmission in the brain (e.g., in the medial prefrontal cortex). And other methods and uses related thereto.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The invention concerns a compound of formula (I) (I) R1═H, —CH3 or acyl group, preferably R1═—CH3R2═H or halogen atom selected in the group consisting of: F, Cl, Br, I, preferably R2═H or a pharmaceutically acceptable isomer, salt and / or solvate thereof, for use in preventing and / or treating neurodegenerative diseases when central muscarinic neurotransmission is compromised, wherein said neurodegenerative disease is selected in the group consisting of Alzheimer's Disease (AD), vascular dementia, Dementia with Lewy bodies (DLB), mixed dementia, frontotemporal lobar degeneration (FTLD), and Parkinson's disease (PD).

A composition of compounds generally represented by Figure 1A for use in substance adjuvant therapy. A method of altering neurotransmission by administering to a mammal a pharmaceutically effective amount of a compound of Figure 1A, interacting with the serotonin 5-HT2A receptor and inducing a psychoactive effect in the mammal, particularly in a human body. A method of treating a subject by administering to the subject a pharmaceutically effective amount of a compound of Figure 1A and treating the subject.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.

This application provides compounds of Formula I described herein, methods for their preparation, their use as pharmaceuticals, pharmaceutical compositions comprising them, and intermediates used in their preparation. Compounds of Formula I can be used, for example, to regulate dopamine and serotonin neurotransmission, and to treat conditions from which they may benefit, such as schizophrenia and depression.

The present invention relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives for use in the prevention or treatment of neurological, psychiatric, sleep disorders and diseases, advantageously in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The invention also relates to pharmaceutical compositions comprising these compounds, their use for the prevention and / or treatment of nervous system disorders and diseases. The invention also relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives, and to the use of these compounds as medicaments.

In some aspects, the disclosure relates to certain siloxine and silosibin analogs, such as tryptamine containing a 4-(2-hydroxyalkyl)-7-alkyl or 4-(2-methoxyalkyl)-7-alkyl substitution on the indole benzene ring. In some aspects, the disclosure relates to pharmaceutical compositions containing these compounds, and methods of using such compounds and compositions to modulate neurotransmission (e.g., serotonergic neurotransmission), modulate neuroplasticity, and treat medical conditions (e.g., inflammatory diseases and conditions). Formula (1)

This disclosure relates in some aspects to novel compounds comprising a substituted benzylpyrrolidine pharmacophore, and analogs thereof. In some aspects, the disclosure further relates to compositions containing the compounds, methods of synthesizing the compounds, and methods of using the compounds. In some aspects, the compounds are useful as therapeutic agents for treating medical conditions, for example by modulating neurotransmission.

The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting / silencing neurotransmission or synaptic transmission of afferent neurons.

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.

The present invention provides an implantable stimulation system having a stimulation unit coupled with a programmable controller, a stimulation circuit, and an array of electrodes arranged on a pair of flexible paddles. [Solution] A programmable controller is pre-programmed to activate an excitation electrode routine that selectively scans an electrode array with a series of directional current flows and optimizes electrode selection for use in stimulating nerves. The implantable stimulation system can be programmed to activate a first stimulation pulse sequence to induce a rapid erectile response corresponding to a first mode, a second nerve function recovery stimulation mode to restore function of neurotransmission in the cavernous nerve, a third penile function recovery mode to reduce penile fibrosis, and / or a fourth bladder nerve function recovery mode to restore function of neurotransmission in the nerves controlling the lower urinary tract.

Provided are compounds of Formula I, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I are useful, for instance, in modulating dopamine neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II as described herein, processes for their preparation, their use as medicaments, pharmaceutical compositions comprising them, and intermediates for their preparation. Compounds of Formula I and Formula II are useful, for example, to modulate dopamine and serotonin neurotransmission, and to treat conditions from which they may benefit, such as schizophrenia and depression.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.

The present invention relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives for use in the prevention or treatment of neurological, psychiatric, sleep disorders and diseases, advantageously in which central orexin neurotransmission is impaired or in which central and peripheral orexin receptors are involved. The invention also relates to pharmaceutical compositions comprising these compounds, their use for the prevention and / or treatment of nervous system disorders and diseases. The invention also relates to dihydroquinazoline, dihydrobenzothiazine and dihydrobenzoxazine derivatives, and to the use of these compounds as medicaments.

The present invention provides a method and pharmaceutical composition for the treatment of overactive bladder (OAB) and / or bladder pain syndrome (BPS), comprising a viral expression vector having a transcription cassette containing one or more transgenes that inhibit / silence neurotransmission or synaptic transmission of afferent neurons.

The present invention relates to a novel chalcone derivative compound and a composition for the prevention or treatment of neurodegenerative diseases, comprising same as an active ingredient. The present invention can fundamentally eliminate the cause of neurotransmission dysfunction by simultaneously inhibiting the activities of two hyperactivated cholinesterases, unlike conventional symptomatic therapies that focus on the control of peripheral symptoms for various neurodegenerative diseases caused by a decrease in acetylcholine concentration, including Alzheimer's disease.

The invention relates to a jasmine flower extract and application thereof. The jasmine flower extract can be used for improving mood and preventing or treating diseases related to neurotransmission impairment. The jasmine flower polypeptide extract does not depend on fragrance, and the effect is remarkable and lasting.

The invention discloses a control concentration improvement method and system based on wearable vibration equipment. In the invention, the negative influence of pressure is obviously reduced through mild alternate vibration, so that the mental health is improved, and the attention is improved. Mechanical vibrations are applied to the body by a vibrating device while the subject is stationary or exercising. Muscle strength, balance, bone mineral density and proprioceptive sensation can be improved. This is a beneficial effect of a short-term attention vibration watch on attention. Along with the prolonging of the duration time of the item, the duration time of the treatment effect of the teenagers with the hyperactivity can be longer. Several related studies for exploring and improving a potential mechanism of cognitive ability show that an attention vibration watch increases activities of tyrosine hydroxylase, BDNF, dopamine and an anterior brain cholinergic system and induces a sensory stimulation cerebral cortex area, and by activating a skin vibration sensitive receptor, neurotransmission of the forehead cortex, the hypothalamus and the amygdala nucleus is influenced, so that the potential mechanism of cognitive ability is improved. The learning and memory are improved, and the attention is improved.